Front Page News
Cure SMA Launches Phase 11 SMA Industry Collaboration
Cure SMA is pleased to announce the launch of Phase 11 initiates for the SMA Industry Collaboration. The SMA Industry Collaboration is a multi-faceted partnership […]
Scholar Rock Resubmits Biologics License Application (BLA) for Apitegromab to the FDA
Today, Scholar Rock announced that it has resubmitted its Biologics License Application (BLA) to the Food and Drug Administration (FDA) for apitegromab, an investigational therapy […]
Biogen Receives FDA Approval of High Dose SPINRAZA for the Treatment of SMA
Biogen today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the High Dose regimen of SPINRAZA (nusinersen) to […]
Cure SMA Awards $150,000 Grant to Tetsuya Akiyama, MD, PhD, Stanford University School of Medicine
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]
Cure SMA Expands Travel Support Package Eligibility to Include Teens with SMA
Cure SMA is excited to share an important update to our travel support programs. In response to community feedback and the growing need for accessible […]
Genentech Issues Community Letter Regarding Emugrobart
Today, Genentech announced the discontinuation of emugrobart (an investigational anti-myostatin antibody, also known as GYM329) into Phase III development for spinal muscular atrophy (SMA). The […]
Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh in Scotland
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]
Cure SMA Awards $150,000 Grant to Christian Simon, PhD, at Leipzig University in Germany
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]
Novartis Releases Winter SMA Community Update Letter
Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with […]
Cure SMA Awards $75,000 Grant to Jiangbing Zhou, PhD, at Yale University
Each year, Cure SMA invites scientists from around the world to submit funding proposals for basic research projects that address specific unanswered questions in spinal […]